

# COVID-19 Outpatient Therapeutics for Healthcare Facilities & Pharmacies in PA

Multiple preventive & treatment options are now authorized by the FDA for emergency use in **outpatient settings**. The Pennsylvania Department of Health (PA DOH) can support your facility in accessing these lifesaving products.

## WHAT COVID-19 THERAPEUTICS (Tx) ARE CURRENTLY ALLOCATED BY PA DOH?

	Oral antivirals (OAVs)	Monoclonal Antibodies (mAbs) for Treatment	Monoclonal Antibodies for Pre-Exposure Prophylaxis (PrEP)
<b>What are they</b>	Oral medications (pills) that prevent multiplication of the COVID-19 virus and help prevent worsening or progression of illness	Intravenous (IV) infusion of antibodies like those produced naturally during COVID-19 infection, preventing worsening or progression of illness	Intramuscular (IM) injection of antibodies that help neutralize the COVID-19 virus to prevent infection and disease in people with compromised immune systems
<b>Who should get them<sup>1</sup></b>	<b>Non-hospitalized patients</b> with mild to moderate COVID-19 over 12 years-old (18+ for Lagevrio)	<b>Non-hospitalized patients</b> over 12 years-old when oral antivirals are not available, feasible to use, or clinically appropriate	<b>Immunocompromised patients</b> and those who are not able to be fully vaccinated with any available COVID-19 vaccines due to a history of severe reactions
<b>When to get them</b>	COVID-positive, <b>within the first 5 days of symptom(s) onset</b>	COVID-positive, <b>within first 7 days of symptom(s) onset</b>	COVID-negative, no known exposure
<b>Currently EUA authorized Tx</b>	<a href="#">Paxlovid</a> (Pfizer) <a href="#">Lagevrio/ molnupiravir</a> (Merck)	<a href="#">Bebtelovimab</a> <sup>2</sup> (Eli Lilly)	<a href="#">Evusheld</a> (AstraZeneca)
<b>Efficacy per clinical trials</b>	Reduction in hospitalizations/deaths: Paxlovid 88%; Lagevrio 30%	Reduction of risk in high-risk patients (clinical trial ongoing)	83% reduction in risk of developing COVID-19 symptoms

1. For more information: ASPR [clinical decision aid](#) & [Tx overview](#). Consult a healthcare professional to confirm eligibility.

2. Federal supply of Bebtelovimab is expected to run out July '22. Providers are encouraged to prescribe Paxlovid if clinically appropriate.

## HOW CAN MY FACILITY ACCESS THESE COVID-19 THERAPEUTICS?

*If you have your own pharmacy on site and/or the ability to prescribe and dispense Tx in your facility...*

### Enroll to be a therapeutics provider with PA DOH

- Complete PA DOH's [therapeutics enrollment form](#)
- You will need to be a registered Health Partner Ordering Portal (HPOP) user. If you aren't already, PA DOH can help create your account upon enrollment. **Your facility needs a pharmacy license and/or a licensed medical director to take responsibility**
- See PA DOH's [COVID-19 therapeutics handbook](#) for more information
- Once you are enrolled, you will receive additional instructions to receive product

*If you use a pharmacy partner that dispenses Tx to you...*

### Check if your pharmacy stocks COVID-19 therapeutics

- To check if your pharmacy has product(s), use this [locator tool](#) or call sites listed on [PA DOH's website](#) to confirm product availability
- If your pharmacy partner does not have product, **inform them of how they can enroll with PA DOH**; send them the link to the [therapeutics enrollment form](#)

## WHERE CAN I FIND ADDITIONAL RESOURCES?

- For more information and the latest updates on COVID-19 therapeutics, please visit: [PA DOH](#), [ASPR](#), [CDC](#), [NIH](#)
- Contact us at [covidtherapeutics@pa.gov](mailto:covidtherapeutics@pa.gov) with any questions